Ariad Presents Positive Data on Iclusig at Annual Hematology Meeting
News
Ariad Pharmaceuticals recently presented data from three studies showing that Iclusig (ponatinib), its approved BCR-ABL inhibitor, provides clinical benefit in leukemia patients who had failed previous treatments with tyrosine kinase inhibitors (TKIs). ... Read more